Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Oct;20 Suppl 2(Suppl 2):S235-42.
doi: 10.1007/s00787-011-0201-5.

Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence

Aribert Rothenberger, Manfred Döpfner
Editorial

Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence

Aribert Rothenberger et al. Eur Child Adolesc Psychiatry. 2011 Oct.

Abstract

Patients with ADHD may have better adherence to treatment with modified-release methylphenidate (MPH-MR) formulations, which are taken once daily, compared with immediate-release (IR) formulations, which need to be taken several times a day. Data on long-term outcomes such as adherence may be lacking from randomised controlled trials as these are usually only short-term. Observational studies, if performed and reported appropriately, can provide valuable long-term data on such outcomes, as well as additional information on effectiveness and efficiency, from a real-life setting. By reviewing previous observational studies that have investigated switching treatment from MPH-IR to MPH-MR, results from a new, naturalistic observational study, the OBSEER study, are put into context. We conclude that, based on observational trial data, switching from MPH-IR to MPH-MR is a valid clinical approach, with the potential for improved clinical outcome and treatment adherence.

PubMed Disclaimer

References

    1. Antes G, Elm E. Wie berichtet man eine Beobachtungsstudie? Deutsches Ärzteblatt. 2008;105:B6.
    1. Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol. 2009;19:673–681. doi: 10.1089/cap.2008.0146. - DOI - PubMed
    1. Bakken RJ, Paczkowski M, Kramer HP, Axelson AA, Williams DW, Malcolm SK, Sumner CR, Kelsey DK. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin. 2008;24:449–460. doi: 10.1185/030079908X253627. - DOI - PubMed
    1. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–495. doi: 10.1007/s00787-006-0549-0. - DOI - PubMed
    1. Banaschewski T, Rothenberger A. Pharmakotherapie mit Stimulanzien bei Kindern und Jugendlichen. In: Steinhausen HC, Rothenberger A, Dopfner M, editors. Handbuch ADHS. Stuttgart: Kohlhammer; 2010. pp. 289–307.

Publication types

MeSH terms

Substances